CD7靶向嵌合抗原受体T细胞疗法治疗T细胞恶性肿瘤的临床疗效与安全性：一项系统评价与Meta分析

Clinical Efficacy and Safety of CD7-Targeted CAR T Cell Therapy for T-cell Malignancies: A Systematic Review and Meta-analysis.

作者信息

Dashti Mohsen, Habibi Mohammad Amin, Nejati Negar, Robat-Jazi Behrouz, Ahmadpour Mahsa, Dokhani Negar, Nejad Aida Rezaei, Karami Shaghayegh, Alinejad Erfan, Malekijoo Amir H, Ghasemzadeh Afsaneh, Jadidi-Niaragh Farhad

机构信息

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Clinical Research Development Center, Qom University of Medical Sciences, Qom, Iran.

出版信息

Anticancer Agents Med Chem. 2025;25(1):42-51. doi: 10.2174/0118715206321313240820101412.

DOI:10.2174/0118715206321313240820101412

PMID:39192642

Abstract

OBJECTIVES

Although T-cell malignancies are relatively less prevalent compared to B-cell malignancies, they are highly malignant, and patients usually have poor prognoses. Employing CD7-targeted chimeric antigen receptor (CAR) T cell therapy as a novel immunotherapy to treat malignant T cells faces numerous challenges and is in its early phase. To evaluate this possibility, we aimed to review and meta-analyze the related clinical trials systematically.

METHODS

On October 9, 2023, the online databases of PubMed, Scopus, Embase, and Web of Science were systematically searched for pertinent studies. After completing a two-step title/abstract and full-text screening process, the eligible studies were included.

RESULTS

We observed a pooled overall response rate (ORR) of 100%. Partial response (PR), stringent and/or complete response (sCR/CR), and relapse rate were 6%, 85%, and 18%, respectively. Additionally, the pooled rate of minimal residual disease (MRD) negativity was 85%. The most common grade ≥3 adverse events were related to hematological toxicities, including neutropenia (100%), thrombocytopenia (79%), and anemia (57%). Cytokine release syndrome (CRS) was also a frequent complication with a 100% rate; however, 81% of CRS events were low grades. No grade ≥3 GVHD was reported, and the immune effector cell-associated neurotoxicity syndrome (ICANS grade ≥3) was rare (4%).

CONCLUSION

CD7 is an active and safe target that shows promising results in the treatment of relapsed and/or refractory (r/r) T-cell malignancies.

摘要

目的

尽管与B细胞恶性肿瘤相比，T细胞恶性肿瘤相对不那么常见，但它们具有高度恶性，患者的预后通常较差。采用靶向CD7的嵌合抗原受体（CAR）T细胞疗法作为一种治疗恶性T细胞的新型免疫疗法面临诸多挑战，且尚处于早期阶段。为评估这种可能性，我们旨在系统回顾并荟萃分析相关临床试验。

方法

2023年10月9日，我们系统检索了PubMed、Scopus、Embase和Web of Science的在线数据库以查找相关研究。在完成两步标题/摘要和全文筛选过程后，纳入符合条件的研究。

结果

我们观察到汇总的总缓解率（ORR）为100%。部分缓解（PR）、严格和/或完全缓解（sCR/CR）以及复发率分别为6%、85%和18%。此外，最小残留病（MRD）阴性的汇总率为85%。最常见的≥3级不良事件与血液学毒性有关，包括中性粒细胞减少（100%）、血小板减少（79%）和贫血（57%）。细胞因子释放综合征（CRS）也是一种常见并发症，发生率为100%；然而，81%的CRS事件为低级别。未报告≥3级移植物抗宿主病（GVHD），免疫效应细胞相关神经毒性综合征（ICANS≥3级）罕见（4%）。